Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).
1 finding from 1 review
Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Intervention not reported
Serious adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in serious adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes serious adverse events during the trial period (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: severe, grade > 2 (Duration of · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in adverse events: severe, grade > 2 (Duration of (low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
1 finding from 1 review
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review